NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, Forecast & News

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

Dova Pharmaceuticals Inc (NASDAQ:DOVA) announced its earnings results on Tuesday, August, 6th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The business earned $3.52 million during the quarter, compared to analysts' expectations of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative return on equity of 101.60%. View Dova Pharmaceuticals' Earnings History.

6 analysts have issued 12 month price objectives for Dova Pharmaceuticals' stock. Their forecasts range from $15.00 to $30.00. On average, they anticipate Dova Pharmaceuticals' stock price to reach $26.42 in the next year. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Dova Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.

News articles about DOVA stock have trended negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a daily sentiment score of -2.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Dova Pharmaceuticals.

Some companies that are related to Dova Pharmaceuticals include Agios Pharmaceuticals (AGIO), Apellis Pharmaceuticals (APLS), Axsome Therapeutics (AXSM), Zai Lab (ZLAB), Genmab A/S (GMAB), Alkermes (ALKS), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Karuna Therapeutics (KRTX), Uniqure (QURE), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), Epizyme (EPZM), Zogenix (ZGNX) and ArQule (ARQL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Sasol (SSL), Aldeyra Therapeutics (ALDX), TESARO (TSRO), TherapeuticsMD (TXMD), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Heron Therapeutics (HRTX) and Immunomedics (IMMU).

(DOVA) raised $66 million in an IPO on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DOVA stock can currently be purchased for approximately $28.04.

Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.

The official website for Dova Pharmaceuticals is http://www.dova.com/.

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]